Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2025-12-27 @ 2:07 AM
Study NCT ID:
NCT02605993
Status:
COMPLETED
Last Update Posted:
2023-01-04
First Post:
2015-11-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sponsor:
Alexion Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-01-04
Start Date Type:
ACTUAL
Primary Completion Date:
2017-02-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-12
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-11
First Submit QC Date:
None
Study First Post Date:
2015-11-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-01-18
Results First Submit QC Date:
None
Results First Post Date:
2019-02-18
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-02-22
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-12-07
Last Update Post Date:
2023-01-04
Last Update Post Date Type:
ACTUAL